Bedini José Luis, Wallace Jane F, Petruschke Thorsten, Pardo Scott
Core Lab, Hospital Clinic, Barcelona, Spain
Bayer HealthCare LLC, Medical Care, Mishawaka, IN, USA.
J Diabetes Sci Technol. 2015 Aug 7;10(1):93-100. doi: 10.1177/1932296815598777.
Self-monitoring of blood glucose is crucial for the effective self-management of diabetes. The present study evaluated the accuracy of the Contour® XT blood glucose monitoring system (BGMS) compared to the reference method in a large multicenter study under routine lab conditions at each hospital site.
This study was conducted at 21 leading hospitals in Spain using leftover whole blood samples (n = 2100). Samples were tested with the BGMS using 1 commercial strip lot and the local laboratory hexokinase method. BGMS accuracy was assessed and results were compared to ISO 15197:2013 accuracy limit criteria and by using mean absolute relative difference analysis (MARD), consensus (Parkes) error grid (CEG), and surveillance error grid analyses (SEG).
Pooled analysis of 2100 measurements from all sites showed that 99.43% of the BGMS results were within the ranges accepted by the accuracy limit criteria. The overall MARD was 3.85%. MARD was 4.47% for glucose concentrations < 70 mg/dL and 3.81% for concentrations of 70-300 mg/dL. In CEG, most results (99.8%) were within zone A ("no effect on clinical action"); the remaining ones (0.2%) were in zone B ("little to no effect on clinical action"). The SEG analysis showed that most of the results (98.4%) were in the "no risk" zone, with the remaining results in the "slight, lower" risk zone.
This is the largest multicenter study of Contour XT BGMS to date, and shows that this BGMS meets the ISO 15197:2013 accuracy limit criteria under local routine conditions in 21 leading Spanish hospitals.
血糖自我监测对于糖尿病的有效自我管理至关重要。本研究在各医院站点的常规实验室条件下,通过一项大型多中心研究,评估了Contour® XT血糖监测系统(BGMS)与参考方法相比的准确性。
本研究在西班牙的21家领先医院使用剩余的全血样本(n = 2100)进行。使用1个商业试纸批次,通过BGMS对样本进行检测,并采用当地实验室己糖激酶法。评估BGMS的准确性,并将结果与ISO 15197:2013准确性限值标准进行比较,同时采用平均绝对相对差分析(MARD)、一致性(帕克斯)误差网格(CEG)和监测误差网格分析(SEG)。
对所有站点的2100次测量进行汇总分析表明,99.43%的BGMS结果在准确性限值标准所接受的范围内。总体MARD为3.85%。血糖浓度<70 mg/dL时MARD为4.47%,浓度为70 - 300 mg/dL时MARD为3.81%。在CEG中,大多数结果(99.8%)处于A区(“对临床行动无影响”);其余结果(0.2%)处于B区(“对临床行动几乎没有影响”)。SEG分析表明,大多数结果(98.4%)处于“无风险”区,其余结果处于“轻微、较低”风险区。
这是迄今为止关于Contour XT BGMS的最大规模多中心研究,表明该BGMS在西班牙21家领先医院的当地常规条件下符合ISO 15197:2013准确性限值标准。